Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Infect Immun ; 75(1): 252-9, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17074855

ABSTRACT

In order to test vaccines against enterotoxigenic Escherichia coli (ETEC)-induced diarrhea, challenge models are needed. In this study we compared clinical and immunological responses after North American volunteers were orally challenged by two ETEC strains. Groups of approximately eight volunteers received 10(9) or 10(10) CFU of E. coli B7A (LT+ ST+ CS6+) or 10(8) or 10(9) CFU of E. coli H10407 (LT+ ST+ CFA/I+). About 75% of the volunteers developed diarrhea after challenge with 10(10) CFU B7A or either dose of H10407. B7A had a shorter incubation period than H10407 (P = 0.001) and caused milder illness; the mean diarrheal output after H10407 challenge was nearly twice that after B7A challenge (P = 0.01). Females had more abdominal complaints, and males had a higher incidence of fever. Ciprofloxacin generally diminished or stopped symptoms and shedding by the second day of antibiotic treatment, but four subjects shed for one to four additional days. The immune responses to colonization factors CS6 and colonization factor antigen I (CFA/I) and to heat-labile toxin (LT) were measured. The responses to CFA/I were the most robust responses; all volunteers who received H10407 had serum immunoglobulin A (IgA) and IgG responses, and all but one volunteer had antibody-secreting cell (ASC) responses. One-half the volunteers who received B7A had an ASC response to CS6, and about one-third had serum IgA or IgG responses. Despite the differences in clinical illness and immune responses to colonization factors, the immune responses to LT were similar in all groups and were intermediate between the CFA/I and CS6 responses. These results provide standards for immune responses after ETEC vaccination.


Subject(s)
Anti-Infective Agents/therapeutic use , Ciprofloxacin/therapeutic use , Dysentery/drug therapy , Dysentery/immunology , Escherichia coli Infections/drug therapy , Escherichia coli Infections/immunology , Dysentery/physiopathology , Enterotoxins/immunology , Escherichia coli , Escherichia coli Infections/physiopathology , Female , Fimbriae Proteins/immunology , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Male , Sex Factors
2.
Am J Trop Med Hyg ; 69(6 Suppl): 17-23, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14740951

ABSTRACT

We describe the results of initial safety testing of 10 live-attenuated dengue virus (DENV) vaccine candidates modified by serial passage in primary dog kidney (PDK) cells at the Walter Reed Army Institute of Research. The Phase 1 studies, conducted in 65 volunteers, were designed to select an attenuated vaccine candidate for each DENV serotype. No recipient of the DENV candidate vaccines sustained serious injury or required treatment. Three vaccine candidates were associated with transient idiosyncratic reactions in one volunteer each, resulting in their withdrawal from further clinical development. Increasing PDK cell passage of DENV-1, DENV-2, and DENV-3 candidate vaccines increased attenuation for volunteers, yet also decreased infectivity and immunogenicity. This effect was less clear for DENV-4 candidate vaccines following 15 and 20 PDK cell passages. Only one passage level each of the tested DENV-2, -3, and -4 vaccine candidates was judged acceptably reactogenic and suitable for expanded clinical study. Subsequent studies with more recipients will further establish safety and immunogenicity of the four selected vaccine candidates: DENV-1 45AZ5 PDK 20, DENV-2 S16803 PDK 50, DENV-3 CH53489 PDK 20, and DENV-4 341750 PDK 20.


Subject(s)
Antibodies, Viral/biosynthesis , Dengue Virus/immunology , Dengue/prevention & control , Viral Vaccines , Adolescent , Adult , Antibodies, Viral/blood , Cells, Cultured , Female , Humans , Male , Middle Aged , Military Medicine , Serial Passage , Single-Blind Method , United States , Vaccines, Attenuated/adverse effects , Viral Vaccines/adverse effects , Viremia
3.
Infect Immun ; 67(7): 3437-43, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10377124

ABSTRACT

The Shigella flexneri 2a SC602 vaccine candidate carries deletions of the plasmid-borne virulence gene icsA (mediating intra- and intercellular spread) and the chromosomal locus iuc (encoding aerobactin) (S. Barzu, A. Fontaine, P. J. Sansonetti, and A. Phalipon, Infect. Immun. 64:1190-1196, 1996). Dose selection studies showed that SC602 causes shigellosis in a majority of volunteers when 3 x 10(8) or 2 x 10(6) CFU are ingested. In contrast, a dose of 10(4) CFU was associated with transient fever or mild diarrhea in 2 of 15 volunteers. All volunteers receiving single doses of >/=10(4) CFU excreted S. flexneri 2a, and this colonization induced significant antibody-secreting cell and enzyme-linked immunosorbent assay responses against S. flexneri 2a lipopolysaccharide in two-thirds of the vaccinees. Seven volunteers who had been vaccinated 8 weeks earlier with a single dose of 10(4) CFU and 7 control subjects were challenged with 2 x 10(3) CFU of virulent S. flexneri 2a organisms. Six of the control volunteers developed shigellosis with fever and severe diarrhea or dysentery, while none of the vaccinees had fever, dysentery, or severe symptoms (P = 0. 005). Three vaccinees experienced mild diarrhea, and these subjects had lower antibody titers than did the fully protected volunteers. Although the apparent window of safety is narrow, SC602 is the first example of an attenuated S. flexneri 2a candidate vaccine that provides protection against shigellosis in a stringent, human challenge model.


Subject(s)
Bacterial Proteins/immunology , Bacterial Vaccines/immunology , Dysentery, Bacillary/immunology , Shigella flexneri/immunology , Bacterial Proteins/genetics , Bacterial Vaccines/administration & dosage , DNA-Binding Proteins/genetics , Dysentery, Bacillary/prevention & control , Genes, Bacterial , Humans , Mutagenesis, Site-Directed , Plasmids , Shigella flexneri/genetics , Transcription Factors/genetics , Vaccination
4.
J Infect Dis ; 172(4): 1126-9, 1995 Oct.
Article in English | MEDLINE | ID: mdl-7561195

ABSTRACT

Cholera vaccine candidate Peru-15 was derived from a Vibrio cholerae O1 El Tor Inaba strain by deleting the cholera toxin genetic element, introducing the gene encoding cholera toxin B subunit into recA, and screening for nonmotility. In a controlled study, Peru-15 (2 x 10(8) cfu) was administered to 11 volunteers. No vaccinee developed diarrhea, and 10 of 11 had > 4-fold rises in vibriocidal antibody titers. One month later, 5 vaccinees and 5 control volunteers were challenged with wild type V. cholerae O1. Four of 5 controls developed diarrhea (mean, 1.9 L). Two Peru-15 vaccinees developed diarrhea, 1 with < 0.3 L and 1 with approximately 1.0 L; this latter volunteer had not developed a significant vibriocidal immune response to vaccination. Peru-15 shows promise as a single-dose, oral cholera vaccine that is safe, immunogenic, and protective.


Subject(s)
Cholera Vaccines/administration & dosage , Cholera Vaccines/therapeutic use , Cholera/prevention & control , Administration, Oral , Adolescent , Adult , Antibodies, Bacterial/blood , Cholera Vaccines/adverse effects , Diarrhea/prevention & control , Humans , Safety , Treatment Outcome , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/adverse effects , Vaccines, Attenuated/therapeutic use , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/adverse effects , Vaccines, Synthetic/therapeutic use
5.
Lancet ; 345(8955): 949-52, 1995 Apr 15.
Article in English | MEDLINE | ID: mdl-7715293

ABSTRACT

New vaccines are needed to prevent cholera caused by Vibrio cholerae O139. Attenuated V cholerae O139 vaccines were made by deleting multiple copies of the cholera-toxin genetic element from two virulent strains of the organism, MO10 and AI4456. The deletion mutants were further modified by insertion of a construct that encoded the B subunit of cholera toxin, thus generating strains Bengal-3 and VRI-16. A stable spontaneous non-motile derivative of Bengal-3 was isolated and designated Bengal-15; VRI-16 is naturally non-motile. Bengal-3, Bengal-15, and VRI-16 were evaluated as oral single-dose cholera vaccine candidates in 4 volunteers each, and MO10 was given to 3 volunteers. 1 of 4 volunteers who received Bengal-3 and all 3 who received MO10 had diarrhoea. VRI-16 caused no significant symptoms but was not immunogenic. Bengal-15 produced few symptoms and was nearly as immunogenic as MO10. Subsequently, Bengal-15 was given to 10 volunteers at a dose of 10(8) colony-forming units. No volunteers had diarrhoea, and other subjective symptoms were as common in vaccinees as in 3 buffer recipients. 1 month after vaccination, 7 vaccinees, the 3 buffer recipients, and 3 unimmunised subjects were challenged with 5 x 10(6) colony-forming units of V cholerae O139. 5 of 6 controls had cholera-like diarrhoea. By contrast, 1 of 7 vaccinees had diarrhoea, which was mild and had a long incubation period. Vaccine protective efficacy was 83%. Our results indicate the Bengal-15 is a safe live attenuated vaccine candidate for cholera caused by the O139 serogroup.


Subject(s)
Cholera Vaccines , Administration, Oral , Adolescent , Adult , Antibodies, Bacterial/blood , Cholera/prevention & control , Cholera Vaccines/administration & dosage , Cholera Vaccines/adverse effects , Cholera Vaccines/immunology , Double-Blind Method , Humans , Vaccines, Attenuated , Vibrio cholerae/immunology
6.
J Infect Dis ; 170(6): 1518-23, 1994 Dec.
Article in English | MEDLINE | ID: mdl-7995992

ABSTRACT

Vibrio cholerae El Tor strains from Peru, Bangladesh, and Bahrain were attenuated by deletion of a genetic element that encodes virulence factors and RS1. The B subunit of ctx (ctxB) was reintroduced into the recA gene of the deletion mutants, rendering them unable to recombine with exogenous genetic elements and generating Peru-3, Bang-3, and Bah-3. Fifteen volunteers received one dose of various vaccine strains at 4 x 10(6) to 1 x 10(8) cfu. All strains colonized the gut. A > or = 4-fold rise in vibriocidal titer was observed in 14 volunteers, with titers of > or = 1600 in 13. Peru-3 was the least reactogenic, but 2 of 6 volunteers had loose stools. Peru-14, a filamentous motility-deficient mutant of Peru-3, was well tolerated and colonized 18 of 21 volunteers at doses of 2 x 10(6) to 1 x 10(9) cfu. Also, when 8 Peru-3 or Peru-5 vaccinees, 5 Peru-14 vaccinees, and 8 controls were challenged with 2 x 10(6) cfu V. cholerae El Tor Inaba (N16961), 11 vaccinees were protected compared with no controls. Peru-14 shows promise as a safe, effective, single-dose oral vaccine against El Tor cholera.


Subject(s)
Cholera Vaccines , Cholera/prevention & control , Adolescent , Adult , Animals , Animals, Suckling , Antibodies, Bacterial/blood , Cholera Vaccines/adverse effects , Cholera Vaccines/genetics , Cholera Vaccines/immunology , Feces/microbiology , Female , Genes, Bacterial/genetics , Humans , Immunoglobulin G/blood , Intestines/microbiology , Male , Mice , Recombination, Genetic , Sequence Deletion , Vaccination , Vaccines, Attenuated/adverse effects , Vaccines, Attenuated/genetics , Vaccines, Attenuated/immunology , Vibrio cholerae/genetics , Vibrio cholerae/growth & development , Vibrio cholerae/immunology , Vibrio cholerae/pathogenicity , Virulence
7.
Chest ; 105(3): 959-61, 1994 Mar.
Article in English | MEDLINE | ID: mdl-8131580

ABSTRACT

Coronary artery fistulas have been traditionally diagnosed by angiography. This report describes a congenital and a traumatic coronary artery fistula diagnosed by transesophageal echocardiography. Transesophageal echocardiography was superior to transthoracic echocardiography in both cases and to angiography in one case. Transesophageal echocardiography may now be the procedure of choice in diagnosing coronary fistula.


Subject(s)
Coronary Disease/diagnostic imaging , Coronary Vessel Anomalies/diagnostic imaging , Echocardiography, Transesophageal , Fistula/diagnostic imaging , Coronary Disease/congenital , Female , Fistula/congenital , Heart Atria , Heart Ventricles , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL